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IINNOVATIONS
The year was 1977, and everyone, from children to adults, was talking about it. Just shy of my seventh birth-day, Dad was taking me to see the biggest movie blockbuster of the year while Mom stayed home with my younger sister. I vividly remember my excitement as we pulled up to the Broadmoor Theatre in Baton Rouge, 
Louisiana, to find the longest box office line I’d ever seen winding around the side of the building! Undeterred, I was 
willing to wait it out - as long as we could get tickets, which we barely did before it sold out. 
As the lights dimmed and the projector started, a crawl appeared on the screen…“A long time ago, in a galaxy 
far, far away…” I was mesmerized for the next two hours by this groundbreaking film that four decades later would 
continue to set records and spawn new blockbuster movies, books, games, television series, comic books, merchan-
dise sales, and even amusement park rides. Star Wars (now a.k.a. A New Hope) made a huge impression on me, and 
countless others, as I imagined myself as Luke Skywalker or Han Solo fighting Darth Vader and the evil Empire. I 
was also awestruck by the two droids who autonomously visualized and navigated their environment; understood 
spoken language, processed its meaning, reasoned a response, and then conversed with other characters; and who 
in many instances outsmarted their human adversaries. Robots weren’t new to me, but R2-D2 and C-3PO displayed 
the most advanced forms of artificial intelligence I’d ever encountered.
Today, artificial intelligence has become so commonplace in society, that many things once considered revolutionary 
are no longer even considered AI. Taking a look back at some of AI’s historical milestones and understanding a few basic 
terms will allow us to better understand several current AI health care projects and their potential impact on eye care.
A BRIEF TIMELINE OF AI
Ancient Times: early mathematicians/philosophers begin studying mechanical reasoning & propose robots, 
automatons, & smart machines
1818: Mary Shelley publishes Frankenstein, one of the earliest examples of AI in science fiction
1943: Warren McCullouch & Walter Pitts publish formal design for “artificial neurons,” the first recog-
nized work of AI
1956: AI formally coined & established at Dartmouth College Conference
1960s: British & U.S. governments/other labs around world invest heavily in AI 
1970s-80s: Advances slow due to competing funding priorities, moral criticisms, & technological 
limitations
Late ‘90s-Early 21st Century: AI used for logistics, data mining, medical diagnosis, & other areas due 
to advances in computational power & data storage1
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INNOVATIONSI
Today, health and well-being is a focal point for AI entrepreneurs, with 1 in 5 AI startups (more than in any other 
sector) devoted to this area (Fig. 1).2 
Figure 1: There are more entrepreneurial AI startups devoted to health and well being (~20% of all startups) than in any 
other sector.2
TERMINOLOGY
Artificial Intelligence (AI) = a broad field attempting to “automate human/cognitive processes” (Fig. 2)
Figure 2: Deep Learning (DL) is a subset of Machine Learning (ML), both powered by Neural Network algorithms to 
continuously improve program performance.  All of these are types of Artificial Intelligence (AI).
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THE FUTURE OF EYE CARE
Neural Networks (aka neural nets) = basis for earliest AI research; modeled after cortical neuron networks in 
the human brain - a single artificial neuron (“N”) accepts input from multiple others, each of which when activated 
cast a weighted vote “for” or “against” whether “N” itself should activate; learning requires an algorithm to adjust 
these weighted votes based on training data, which can then identify hidden relationships & patterns in raw data, 
organize & classify it, & continuously learn & improve over time.3
Machine Learning (ML) = a subfield of AI that drove research from 1980’s-2010’s; aims to develop programs 
(aka models) via exposure to training data alone, then spontaneously & continuously improve themselves; e.g. self-
driving cars, fraud detection algorithms, & personalized suggestions online merchandisers provide based on past 
history.3 
Deep Learning (DL) = one of many subfields of ML; any artificial neural network which can learn a long chain 
of causal links; the models then form stacks of layers which train the computer to learn on its own4,5; all of today’s 
leading AI research involves DL neural nets.
CURRENT HEALTH CARE AI PROJECTS
Hanover
Microsoft developed this AI platform to advance the state of the art of machine reading to accelerate “curation 
as a service” in precision medicine. Basically, the goal is to automate and exponentially enhance the process of read-
ing a cancer patient’s genomics data; analyzing all diagnosis-specific, evidence-based medicine available; reviewing 
relevant clinical trials and treatment protocols; and enrolling patients in the trial protocol which offers the greatest 
chances for a cure. This is all done in conjunction with a doctor’s oversight.6
Deep Mind
The Deep Mind Artificial Intelligence Computer Program was founded in 2010 in London, before being bought 
by Google in 2014. It taught itself to play 49 different video games with only raw pixel input, and researchers at 
Moorfield’s Eye Hospital (London) have now input over 1 million anonymized retinal photographs that had already 
been flagged for signs of disease, allowing the AI algorithm to teach itself how to recognize the signs of ocular dis-
ease. This AI system can interpret scans from clinical practice with unprecedented speed and accuracy, correctly 
recommending how patients should be referred for treatment for over 50 sight-threatening conditions as accurately 
as leading experts.7 
Watson
IBM researchers in Australia have trained their artificial intelligence platform, Watson, to detect abnormalities 
in retinal photographs to identify posterior segment diseases like age-related macular degeneration (AMD), diabet-
ic retinopathy (DR), and glaucoma earlier than can existing strategies. Investigators at the University of Melbourne 
input 88,000 retinal images to Watson, and through DL techniques it was able to measure cup-to-disc ratio and 
determine signs of glaucoma with up to 95%.8 Another study by researchers in New York in conjunction with Wat-
son was recently published showing a diagnostic accuracy rate of 94% for glaucoma by analyzing optical coherence 
tomography scans.9 Watson has also been used to increase graduation rates for guide dogs for the visually impaired 
by 20% by identifying those dogs most likely to succeed in those rigorous training programs based on genetic maps, 
breeders, trainers, and veterinary medical records.10
IDx-DR
IDx is developing feature-recognition-based AI algorithms to automate the diagnosis of glaucoma, AMD, and 
DR. This algorithm is programmed to look for signs of retinal disease (versus the ML-based AI utilized by the 
other algorithms presented here). The company’s IDx-DR platform received U.S. Food & Drug Administration ap-
proval in 2018, becoming the first standalone, AI-driven retinal image analyzer. The algorithm is specifically paired 
with Topcon’s NW400 Retinal Camera, which then scans and analyzes images for DR without human intervention 
post-image acquisition. In short order, the software provides doctors with an assessment of whether “more than 
mild” diabetic retinopathy is present. If so, the patient is referred to an eye care professional, and if the screening 
is negative, it’s recommended the patient return in 12 months for repeat analysis. Initial studies demonstrate 87.2% 
sensitivity and 90.7% specificity.11,12 
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Ambient Clinical Intelligence (ACI)
Nuance is marketing this platform as a way to help mitigate health care provider burnout from excessive time navi-
gating patient charts and completing documentation details. ACI “listens” to clinicianpatient conversations and inter-
faces with the EHR to facilitate workflows and enhance automation of tasks and clinical knowledge. It automatically 
documents patient care interactions without distracting the physician’s attention from their patient. By utilizing wall-
affixed hardware containing 16 microphones and voice biometrics for security purposes (e.g. authentication, speaker 
identification, patient consent & physician document signing), the doctor can also complete medication orders and 
sign the note using an embedded virtual assistant. The hardware/software combination captures what patients and 
providers say, with relevant patient responses automatically added to the chart, thus eliminating the need for the doc-
tor to manually enter it later. Successful pilot trials are in place now, with a widespread launch planned for 2020.13,14,15
Others
Numerous electronic health record companies and practice management software firms are working to incorpo-
rate AI into their products, as well, to maximize scheduling, patient flow, payor management, optical administra-
tion, and a host of other areas. Thanks to AI, small-to-medium sized practices may soon have access to cutting edge 
technologies and management strategies that were perhaps out of reach beforehand due to resource limitations and 
the high costs previously associated with them.
POTENTIAL IMPACTS ON EYE CARE
All of these AI products offer the ability to analyze enormous volumes of data with the potential to streamline 
and enhance quality of care and patient outcomes. As one colleague in Texas aptly noted, who owns the data, where 
it’s housed, and how it's accessed will be critical, especially as some companies fold in the future. So what does all 
this mean for optometry? Will massive changes occur to the way we practice, threatening to replace the care we 
provide with AI driven devices, instead of human doctors, or will the status quo largely prevail? Will refractive eye 
care become the purview of automated AI systems and apps without appropriate doctor oversight?
Personally, despite all the advances in AI to-date, I don’t think we’re in danger of being replaced by Drs. R2-D2 
and C-3PO any time soon. Recent studies have shown early AI algorithms may not perform as well in real-world 
clinic settings as in controlled study environments,16 but that will certainly improve over time. Additionally, re-
search is showing that AI, in combination with doctor interpretation, is more accurate than either option alone.17 
As long as we continue to provide our patients with excellent care, listen to their needs, stay abreast of the latest 
innovations in eye care, and remain open to the appropriate adoption of new technologies, there will always be a 
place for us. However, should we bury our head in carbonite we run the risk of experiencing the same fate as the 
Death Star. AI can exponentially elevate the care we provide when implemented the right way, and it’s incumbent 
upon us to be involved early and advocate for our patients as new developments emerge. 
With Microsoft, Google, and IBM involved in health care AI, there’s sure to be something that comes of it. I cer-
tainly don’t claim to know exactly how or when, but one thing is abundantly clear - change is coming, and those who 
aptly embrace it will best be poised for future success. May the Force be with you! l
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